You have 1 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

Oral disease modifying treatments

Showing 1 - 25 of >10,000
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

Long Term Trajectories of SMA Patients Receiving or Not

Recruiting
  • Spinal Muscular Atrophy
    • Genova, Italy
    • +4 more
    Mar 2, 2023

    C10.114.375.500 Trial in Lille, Caen, Rouen (Delay between MS onset and introduction of first line DMT, EDI)

    Completed
    • C10.114.375.500
    • Delay between MS onset and introduction of first line DMT
    • EDI
    • Lille, Hauts-de-France, France
    • +3 more
    Oct 20, 2020

    MAP THE SMA:Machine-learning Based Algorithm to Predict

    Not yet recruiting
    • Spinal Muscular Atrophy
    • disease modifying treatments
    • (no location specified)
    Mar 14, 2023

    First-line DMD Treatments for Multiple Sclerosis (CLAD CROSS)

    Active, not recruiting
    • Multiple Sclerosis
    • Alexandroupolis, Greece
    • +52 more
    Sep 28, 2022

    Amyotrophic Lateral Sclerosis Trial in France (Deferiprone, Placebo Oral Tablet)

    Active, not recruiting
    • Amyotrophic Lateral Sclerosis
    • Angers, France
    • +14 more
    Nov 4, 2022

    Multiple Sclerosis Trial in Atlanta, Worcester, Salt Lake City (IMS001)

    Recruiting
    • Multiple Sclerosis
    • IMS001
    • Atlanta, Georgia
    • +2 more
    Sep 20, 2021

    Alzheimers Disease, Dementia, Alzheimers Disease, Familial Trial in Worldwide (Gantenerumab, Solanezumab, Matching Placebo

    Completed
    Has Results
    • Alzheimers Disease
    • +2 more
    • Birmingham, Alabama
    • +24 more
    Aug 25, 2022

    Alzheimers Disease, Dementia, Alzheimers Disease, Familial Trial in Worldwide (Gantenerumab, Matching Placebo (Gantenerumab))

    Suspended
    • Alzheimers Disease
    • +2 more
    • Birmingham, Alabama
    • +34 more
    Jan 10, 2023

    Treatments and Outcomes in Real-World Setting

    Recruiting
    • Headache Disorders, Secondary
    • +6 more
    • Clinical evaluation
    • Valladolid, Spain
      Hospital Clínico Universitario de Valladolid
    Aug 12, 2022

    Neurological Disorder, Autoimmune Diseases Trial in Canada, United States (Mycophenolate Mofetil, Azathioprine)

    Completed
    • Neurological Disorder
    • Autoimmune Diseases
    • Palo Alto, California
    • +18 more
    Feb 2, 2021

    Spinal Cord Injuries, Osteoporosis, Metabolic Syndrome Trial in Miami, Toronto (Rosuvastatin Calcium, Placebo Oral Tablet,

    Active, not recruiting
    • Spinal Cord Injuries
    • +2 more
    • Rosuvastatin Calcium
    • +4 more
    • Miami, Florida
    • +1 more
    Oct 19, 2021

    Multiple Sclerosis, Multiple Sclerosis, Relapsing-Remitting Trial in Germany, United States (Tetanus, diphtheria, and acellular

    Recruiting
    • Multiple Sclerosis
    • Multiple Sclerosis, Relapsing-Remitting
    • Tetanus, diphtheria, and acellular pertussis vaccine
    • +2 more
    • Palo Alto, California
    • +47 more
    Jun 24, 2022

    Alzheimers Disease, Dementia, Alzheimers Disease, Familial Trial in Worldwide (Gantenerumab, Solanezumab, Matching Placebo

    Recruiting
    • Alzheimers Disease
    • +2 more
    • Birmingham, Alabama
    • +38 more
    Nov 1, 2021

    A Post-Authorization, Long-term Study of Ozanimod Real-world

    Active, not recruiting
    • Multiple Sclerosis, Relapsing-Remitting
      • Bethesda, Maryland
        Evidera
      Oct 31, 2022

      Oral Health Trial in Bergen (Caries and Obesity Prevention)

      Recruiting
      • Oral Health
      • Caries and Obesity Prevention
      • Bergen, Norway
      • +1 more
      Feb 24, 2023

      Healthy Volunteers Trial in Quebec (ATH-399A, Placebo)

      Recruiting
      • Healthy Volunteers
      • Quebec, Canada
        Syneos Quebec Canada
      Oct 11, 2023

      Rheumatoid Arthritis Trial in Pierre-Bénite, Lyon (Pharmaceutical care in multiprofessional collaboration)

      Recruiting
      • Rheumatoid Arthritis
      • Pharmaceutical care in multiprofessional collaboration
      • Pierre-Bénite, Lyon, France
      • +1 more
      Jun 30, 2022

      ACL Injury, Meniscus Tear, Post-traumatic Osteoarthritis Trial in Lexington (Montelukast, Placebo)

      Recruiting
      • ACL Injury
      • +2 more
      • Lexington, Kentucky
        UK Healthcare at Turfland
      Sep 12, 2022

      d in the Treatment of Multiple Sclerosis

      Not yet recruiting
      • Multiple Sclerosis
      • Measurement of concentrations of orally-used DMDs
      • +3 more
      • Ostrava, Moravian-Silesian Region, Czechia
      • +1 more
      Dec 5, 2022

      Describe Switching FromFirst- or Second-line Disease Modifying

      Not yet recruiting
      • Multiple Sclerosis, Relapsing-Remitting
        • (no location specified)
        Dec 12, 2022

        Relationship Between Oral DMT Burden and Adherence in MS

        Enrolling by invitation
        • Multiple Sclerosis
        • Adherence, Medication
        • Melbourne, Victoria, Australia
          Monash University
        Aug 28, 2022

        Relapsing Remitting Multiple Sclerosis Trial in Worldwide (Pleneva TM BGC20-0134, Placebo)

        Terminated
        • Relapsing Remitting Multiple Sclerosis
        • Pleneva TM BGC20-0134
        • Placebo
        • Gent, Belgium
        • +34 more
        Jun 2, 2022

        Multiple Sclerosis, Secondary Progressive, Multiple Sclerosis Trial in Warsaw (Cladribine Subcutaneous Injection, 0.9% Chloride

        Recruiting
        • Multiple Sclerosis, Secondary Progressive
        • Multiple Sclerosis
        • Cladribine Subcutaneous Injection
        • 0.9% Chloride Injection Sodium
        • Warsaw, Mazowieckie, Poland
          Institute of Psychiatry and Neurology
        Jul 26, 2023

        Primary Sjögren's Syndrome (pSS) Trial in Le Kremlin-Bicêtre (Hydroxychloroquine 400mg/d, Leflunomide 20mg/d, Mycophenolate

        Recruiting
        • Primary Sjögren's Syndrome (pSS)
        • Hydroxychloroquine 400mg/d
        • +5 more
        • Le Kremlin-Bicêtre, France
          Raphaele Seror
        May 2, 2022

        Multiple Sclerosis Trial in Clermont-Ferrand (Methylprednisolone, Placebo, natalizumab (NTZ))

        Recruiting
        • Multiple Sclerosis
        • Clermont-Ferrand, France
          CHU Clermont-Ferrand
        Jan 5, 2023